Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.

CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). How CDKN2A and other 9p21 gene co-deletions affect EAC evolution remains understudied. We explored the effects of 9p21 loss in EACs and cancer progressor and non-progressor BEs with matched genomic, transcriptomic and clinical data.

to: Breast implant-associated Epstein-Barr virus-positive large B-cell lymphomas: a report of three cases.

In reference to our paper published in the August issue 2020 of Haematologica,1 the sentence "funded by the European Union Next Generation EU, funds that finance the actions of the Recovery and Resilience Mechanism (RRM)" in the Funding was missing. We need to add it to justify the project. So the Funding paragraph should read as follows: Funding: this work was supported by grants from the Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Economy and Competence, co-funded by European Union (FEDER) (ERDF/ESF, "A way to make Europe"/"Investing in your future" (MINECO, ISCIII) funded by the European Union Next Generation EU, funds that finance the actions of the Recovery and Resilience Mechanism (RRM) (Plan Nacional I+D+I: PI17/02172, PI21/01724, 15826/004, 41163/005 and PMP21/00015), AECC, the Madrid Autonomous Community and STARTUP2020/L2566.

System transferability of Raman-based oesophageal tissue classification using modern machine learning to support multi-centre clinical diagnostics.

Background: The clinical potential of Raman spectroscopy is well established but has yet to become established in routine oncology workflows. One barrier slowing clinical adoption is a lack of evidence demonstrating that data taken on one spectrometer transfers across to data taken on another spectrometer to provide consistent diagnoses.

Methods: We investigated multi-centre transferability using human oesophageal tissue.

Best-Practice Biomarker Testing of Oesophago-Gastric Cancer in the UK: Expert Consensus Recommendations Developed Using a Modified Delphi.

Aims: Oesophago-gastric cancers (OGCs) are amongst the most commonly diagnosed malignancies worldwide and are associated with high disease-related mortality. Predictive biomarkers are molecules that can be objectively measured and used to indicate a likely response to therapeutic intervention, thus facilitating individualised cancer therapy. However, there remains variation in uptake and implementation of biomarker testing across the UK.